Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT03811236 Sponsor: Medical University of Vienna Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT03811236
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your body mass index (BMI) is between 28 and 40 (which falls in the overweight to obese range)
  • More than 10% of your liver is made up of fat, as measured by a scan

Who may not be able to join:

  • You have a hormone or gland disorder (such as thyroid disease that is not being treated, or type 2 diabetes with poorly controlled blood sugar levels) (confirm with trial site)
  • You currently take certain blood pressure medications, specifically beta-blockers, alpha-blockers, or rilmenidine
  • You have chronic kidney disease
  • You have inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)
  • You have an active cancer
  • You have an autoimmune disease (where your immune system attacks your own body)
  • You regularly drink a large amount of alcohol, or more than roughly 2–3 drinks per day for men or 1–2 drinks per day for women
  • A blood test shows that your iron levels are too high (transferrin saturation above 40%)
  • A blood test shows that certain protective proteins in your blood are too low (alpha-1 antitrypsin or ceruloplasmin below set levels) (confirm with trial site)
  • Blood tests suggest signs of autoimmune liver disease or a hepatitis infection
  • You have liver cirrhosis (severe liver scarring)
  • You have high blood pressure in the vein that leads to your liver (portal hypertension)
  • You are pregnant
  • You have any reason you cannot have an MRI scan (for example, a metal implant or pacemaker)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Florian Kiefer, MD, PhD, Medical University of Vienna

Phone: +43140400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 January 2019
Est. completion
1 December 2025

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Hepatic lipid content (%)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov